Search Results - Sarah K. Tasian

Refine Results
  1. 1
    Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled?

    Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled? by Sarah K. Tasian

    Published 2018
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL)

    CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL) by Sarah K. Tasian, Rebecca Gardner

    Published 2015
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  3. 3
    Relapsed pediatric acute myeloid leukaemia: state-of-the-art in 2023

    Relapsed pediatric acute myeloid leukaemia: state-of-the-art in 2023 by Grace Egan, Sarah K. Tasian

    Published 2023
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  4. 4
    Understanding the Biology of CRLF2-Overexpressing Acute Lymphoblastic Leukemia

    Understanding the Biology of CRLF2-Overexpressing Acute Lymphoblastic Leukemia by Sarah K. Tasian, Mignon L. Loh

    Published 2011
    Get full text
    Revisão
    Save to List
    Saved in:
  5. 5
    Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics

    Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics by Sarah K. Tasian, Stephen P. Hunger

    Published 2016
    Get full text
    Revisão
    Save to List
    Saved in:
  6. 6
    Clinical diagnostics and treatment strategies for Philadelphia chromosome–like acute lymphoblastic leukemia

    Clinical diagnostics and treatment strategies for Philadelphia chromosome–like acute lymphoblastic leukemia by Richard C. Harvey, Sarah K. Tasian

    Published 2020
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  7. 7
    Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies

    Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies by Sarah K. Tasian, David T. Teachey, Susan R. Rheingold

    Published 2014
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  8. 8
    Childhood acute lymphoblastic leukemia: Integrating genomics into therapy

    Childhood acute lymphoblastic leukemia: Integrating genomics into therapy by Sarah K. Tasian, Mignon L. Loh, Stephen P. Hunger

    Published 2015
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  9. 9
    Philadelphia chromosome–like acute lymphoblastic leukemia

    Philadelphia chromosome–like acute lymphoblastic leukemia by Sarah K. Tasian, Mignon L. Loh, Stephen P. Hunger

    Published 2017
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  10. 10
    Influenza‐associated morbidity in children with cancer

    Influenza‐associated morbidity in children with cancer by Sarah K. Tasian, Julie R. Park, Emily T. Martin, Janet A. Englund

    Published 2008
    Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (INCB18424-269/AALL1521): Dose-Finding Results from the Part 1 Safety Phase

    A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (INCB18424-269/AALL1521): Dose-Finding Results from the... by Sarah K. Tasian, Albert Assad, Deborah Hunter, Yining Du, Mignon L. Loh

    Published 2018
    Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    A parsimonious 3-gene signature predicts clinical outcomes in an acute myeloid leukemia multicohort study

    A parsimonious 3-gene signature predicts clinical outcomes in an acute myeloid leukemia multicohort study by Sarah Wagner, Jayakumar Vadakekolathu, Sarah K. Tasian, Heidi Altmann, Martin Bornhäuser, A. Graham Pockley, Graham Ball, Sergio Rutella

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Histology of Testicular Biopsies Obtained for Experimental Fertility Preservation Protocol in Boys with Cancer

    Histology of Testicular Biopsies Obtained for Experimental Fertility Preservation Protocol in Boys with Cancer by Eugene J. Pietzak, Gregory E. Tasian, Sarah K. Tasian, Ralph L. Brinster, Claire Carlson, Jill P. Ginsberg, Thomas F. Kolon

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Children's Oncology Group blueprint for research: Acute lymphoblastic leukemia

    Children's Oncology Group blueprint for research: Acute lymphoblastic leukemia by Elizabeth A. Raetz, Deepa Bhojwani, Meenakshi Devidas, Lia Gore, Karen R. Rabin, Sarah K. Tasian, David T. Teachey, Mignon L. Loh

    Published 2023
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells

    Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells by Sarah K. Tasian, Jessica Casas, David Posocco, Shilpa Gandre-Babbe, Alyssa Gagne, Liang Ge, Mignon L. Loh, Mitchell J. Weiss, Deborah L. French, Stella T. Chou

    Published 2018
    Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: the role of kinase type and SH3 domain

    Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: the role of kinase type and SH3 domain by Inge van Outersterp, Sarah K. Tasian, Caitlin E. J. Reichert, Aurélie Boeree, Hester A. de Groot‐Kruseman, Gabriele Escherich, Judith M. Boer, Monique L. den Boer

    Published 2024
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against <i>FLT3</i>- mutant acute myeloid leukemia and <i>KMT2A</i>-rearranged acute lymphoblastic leukemia

    Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against <i>FLT3</i>- mutant acute myeloid leukemia and <i>KMT2A</i&... by Lisa M Niswander, Zachary Graff, Christopher D. Chien, John Chukinas, Christina A. Meadows, Lillie Leach, Joseph P. Loftus, M. Eric Kohler, Sarah K. Tasian, Terry J. Fry

    Published 2022
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)

    A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consorti... by Mignon L. Loh, Sarah K. Tasian, Karen R. Rabin, Patrick A. Brown, Daniel Magoon, Joel M. Reid, Xuejun Chen, Charlotte H. Ahern, Brenda J. Weigel, Susan M. Blaney

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells

    Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells by Saar Gill, Sarah K. Tasian, Marco Ruella, Olga Shestova, Yong Li, David L. Porter, Martin Carroll, Gwenn Danet-Desnoyers, John Scholler, Stephan A. Grupp, Carl H. June, Michael Kalos

    Published 2014
    Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design

    Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design by Haiying Qin, Lila Yang, John Chukinas, Nirali N. Shah, Samiksha Tarun, Marie Pouzolles, Christopher D. Chien, Lisa M Niswander, Anthony Welch, Naomi Taylor, Sarah K. Tasian, Terry J. Fry

    Published 2021
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: